Prevest Denpro Q1 FY27: consolidated PAT +28% YoY to ₹5.64 Cr, margins expand
PAT +28% YoY · revenue +20.95% · margins expanding
₹19.07 Cr
+20.95% YoY
₹5.64 Cr
+28% YoY
27.66%
+1.6pp YoY
₹4.7
Prevest Denpro's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 20.9% YoY to ₹19.07 Cr from ₹15.77 Cr, while consolidated PAT climbed 28.0% YoY to ₹5.64 Cr from ₹4.41 Cr (EPS ₹4.70 vs ₹3.67). Sequentially the print was roughly flat — revenue +0.7% and PAT -3.1% versus the seasonally stronger Q4 FY26 (₹18.94 Cr revenue, ₹5.82 Cr PAT) — a minor QoQ dip that is supporting detail, not the headline. Both profitability metrics expanded YoY: net margin (PAT/total income) rose to 27.7% from 26.0%, and EBITDA margin to 35.5% from 33.7%, even as the company absorbed a fresh ₹27.80 lakh employee-cost impact this quarter from India's newly implemented Labour Codes (effective April 1, 2026) — margin expansion happened despite, not because of, cost trends.
Q1 FY-2027 vs prior quarters
No consensus/street estimates for this quarter turned up in a web search, so vsStreet is unknown; this is a small-cap with limited analyst coverage. Against management's own prior guidance (November 2025 concall) of revenue growth crossing 20% in H2 FY26, the >20% YoY growth now printing in Q1 FY27 shows that trajectory persisting beyond the originally guided window, though it isn't a direct test of that specific guided period. The longer-term ₹100 Cr revenue target (3-year horizon, via scaling U.S. operations) remains distant — FY26 full-year consolidated revenue was ₹71.81 Cr, and the foreign subsidiaries (Axiodent Inc., Prevest Denpro Gulf LLC) contributed a combined ₹5.71 lakh revenue and a ₹16.81 lakh net loss this quarter, immaterial to the group per the auditors.
The stock went into the print at ₹378.5, down 2.9% over the past month of trading.
Management expects revenue growth to accelerate and cross 20% in H2 FY26, driven by a rebound in domestic sales and sustained export momentum. The company is committed to maintaining its high-margin profile by focusing on new value-added product lines, particularly in digital dentistry, disinfectants, and biomaterials.
— This quarter: met
Standalone PAT (₹5.78 Cr, EPS ₹4.82) came in higher than consolidated (₹5.64 Cr, EPS ₹4.70), a ~2.6% gap driven by subsidiary-level losses — not a material divergence but worth flagging since standalone is the number readers may see first. The Board also recommended a final dividend of ₹1 per share (10% of face value) for FY26, subject to AGM approval, and had formally appointed ADV & Associates as statutory auditor for FY27 in late May — routine governance items with no bearing on this quarter's operating print. No management press release accompanied this filing, so there is no fresh management commentary beyond the numbers and standard notes.
W1
Whether YoY revenue growth holds above the 20% mark management targeted for H2 FY26 acceleration, now visible for a further quarter (Q1 FY27: 20.9% YoY)
W2
Progress of U.S. arm Axiodent Inc. toward the ₹100 Cr three-year revenue goal — currently near-negligible (~₹5-6 lakh/quarter combined with Gulf LLC, and loss-making)
W3
Whether the ₹27.80 lakh/quarter Labour Code cost stays a one-time step-up or recurs, and whether OPM (35.5% this quarter) holds as it becomes a run-rate item